A case before a federal judge in Texas could have dramatic effects on abortion access nationwide as anti-abortion groups target the decades-long government approval of a key abortion drug.

A decision is expected by Feb. 24 at the earliest in a case attempting to reverse the FDA’s approval of mifepristone, a medication that can be used with another drug called misoprostol to end a pregnancy. A ruling was previously expected by Friday at the earliest, but a judge issued an order extending the briefing process.

A coalition led by the conservative legal advocacy organization Alliance Defending Freedom filed the lawsuit Nov. 18 in federal court in Amarillo, Texas, arguing the drug comes with medical risks and should be pulled from the market. 

PREVIOUSLY:George Washington University installs emergency contraception vending machine for students

There could be a nationwide ban on abortion pills 

If the judge rules in favor of the anti-abortion coalition, abortion access advocates say it could effectively ban mifepristone nationwide, creating severe consequences on people’s ability to access critical abortion and miscarriage care, especially after the overturning of Roe v. Wade.

The decision “will unleash a public health crisis by removing health care options for millions of people,” said Jenny Ma, senior counsel at the Center for Reproductive Rights.

A ruling in the anti-abortion groups’ favor could mean healthcare providers will be barred from prescribing mifepristone even in states where abortion is legal. In-clinic, procedural abortion care would not be affected by the ruling.

“I think people find it shocking when they learn this will affect the abortion access of everyone across the country even in the bluest of blue states,” said Lorie Chaiten, senior staff attorney at the ACLU’s Reproductive Freedom Project.

WHAT TO KNOW ABOUT ABORTION PILLS:Medication abortion may be the next focal point in the fight over abortion access